Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - Pharma Research BIO/Genor Biopharma

Next Previous
Drug Profile

Trastuzumab biosimilar - Pharma Research BIO/Genor Biopharma

Alternative Names: Coprelotamab - Genor Biopharma; GB 221; Herceptin biosimilar - Pharma Research BIO/Genor Biopharma

Latest Information Update: 20 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genor Biopharma
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HER2 positive breast cancer
  • No development reported Breast cancer

Most Recent Events

  • 20 Sep 2022 Phase-III clinical trials in Her2 positive Breast cancer (Metastatic disease, First-line therapy) in China (IV), before September 2022 (Genor Biopharma website, September 2022)
  • 12 May 2021 Genor Biopharma plans to file NDA to National Medical Products Administration (NMPA) for Breast cancer (Genor Biopharma pipeline, April 2021)
  • 19 Sep 2019 Genor Biopharma completes a phase I trial in Breast cancer in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top